Key facts
- This page summarizes Jonathan Allan's Form 4 filing for Stoke Therapeutics, Inc. (STOK).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Dec 2024, 16:14.
Jonathan Allan - 01 Dec 2024 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)
- Reporting relationship
- GENERAL COUNSEL & CORP SEC
- Issuer ticker
- STOK
- Reported as of
- 01 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Dec 2024, 16:14:20 UTC
- Prior SEC filing
- 22 May 2024
- Next SEC filing
- 05 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Allan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Allan filed Form 4 for Stoke Therapeutics, Inc. (STOK) on 03 Dec 2024.
Change
- Previous filing in this sequence was filed on 22 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
STOK
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +33,927
- Change %
- +691%
- Price
- $0.000000
- Shares after
- 38,838
- Date
- 01 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
STOK
transaction
Derivative
Restricted Stock Unit (RSU)
Options Exercise
- Transaction value
- $0
- Shares
- -33,927
- Change %
- -73%
- Price
- $0.000000
- Shares after
- 12,357
- Date
- 01 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 33,927
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reported total includes an aggregate 2,313 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F3
33,927 restricted stock units vest on December 1, 2024 and 12,357 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.